Nanobiotix Reports Final Phase 1 Results for NBTXR3 in Melanoma

Nanobiotix has released final data from a Phase 1 study of JNJ-1900 (NBTXR3) combined with immune checkpoint inhibitors as treatment for advanced primary cutaneous melanoma resistant to anti-PD-1 therapies. The study included 24 heavily pre-treated patients, revealing a 41.7% overall response rate and a 75% disease control rate. The median overall survival for participants was 17.8 months.

The treatment involved an intratumoral injection of NBTXR3, followed by radiotherapy and either nivolumab or pembrolizumab. The approach demonstrated an acceptable safety profile and promising early efficacy signals, encouraging further exploration in larger trials. An exploratory analysis identified an increase in IL-1β cytokine, suggesting treatment-related immune activation.

The study was presented by Dr. Jason Chan during the European Society for Medical Oncology congress, indicating the feasibility of the treatment strategy across various melanoma lesions and noting responses in non-injected lesions. The findings support further investigation of NBTXR3 in randomized studies.